EU backs AstraZeneca, Daiichi's ENHERTU

AstraZeneca and Daiichi Sankyo’s Enhertu Enhances Stomach Cancer Case With Phase III Win
The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers.
Daiichi Sankyo and AstraZeneca report positive result in trial for its gastric cancer treatment
Daiichi Sankyo and AstraZeneca (NASDAQ:AZN) announced that their drug ENHERTU has demonstrated a statistically significant and clinically meaningful improvement in main goal for its gastric or gastroesophageal junction cancer trial.
AstraZeneca-Daiichi Sankyo Enhertu recommended for approval in EU for patients with HER2-low or HER2-ultralow metastatic breast cancer
Cambridge: AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients
AstraZeneca, Daiichi Sankyo’s Enhertu recommended for approval in EU
AstraZeneca (AZN) and Daiichi Sankyo’s (DSNKY) trastuzumab deruxtecan has been recommended for approval in the European Union as a monotherapy
EU backs AstraZeneca, Daiichi's Enhertu for breast cancer treatment post endocrine therapy
The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer treatment for patients who received endocrine therapy but are not suitable for additional hormone treatments.
AstraZeneca's metastatic breast cancer treatment gets EU recommendation
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo said on Friday that the European Medicines Agency (EMA) endorsed ENHERTU for the treatment of metastatic breast cancer. Issuing a positive recommendation, EMA’s Committee for Medicinal Products for Human Use (CHMP)  recommended the marketing authorization for ENHERTUas a monotherapy for the treatment of
AstraZeneca Enhertu recommended for approval in EU by CHMP
Daiichi Sankyo and AstraZeneca’s Enhertu has been recommended for approval in the European Union as a monotherapy for the treatment of adult patients with unresectable or metast
pharmaphorum1h
Enhertu extends survival in advanced gastric cancer
Enhertu already has seven FDA approvals across breast cancer, gastric cancer, non-small cell lung cancer (NSCLC), and ...
FiercePharma20h
AstraZeneca, Daiichi unblind Enhertu study early as star ADC helps stomach cancer patients live longer
AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...
Seeking Alpha1mon
Daiichi Sankyo sees ENHERTU sales reaching ¥539.9B in FY2024 amid oncology momentum
Analysts flagged concerns over achieving oncology revenue targets amid dependency on ENHERTU’s growth to offset Datroway’s shortfall. Daiichi Sankyo’s Q3 FY2024 results reflect strong ...
pharmaphorum2d
NICE blocks Enhertu use after pricing talks break down
NICE and drugmakers AstraZeneca and Daiichi Sankyo have all expressed their disappointment at being unable to agree on a price for Enhertu that would allow it to be used on the NHS for people ...
Yahoo Finance1mon
FDA expands Enhertu approval to include HER2-ultralow breast cancer patients
AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from the US Food and Drug Administration (FDA) for an expanded indication of ...